Fed Circuit dismisses West-Ward appeal in Novartis suit
The Federal Circuit has ruled that a Novartis patent is valid despite an error of reasoning from a district court.
Clean sweep for AbbVie in Humira litigation
Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira.
Google fund invests in CRISPR start-up
Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
44 states accuse big pharma of price fixing generics market
44 US states have filed a joint complaint against 20 drug companies, alleging they engaged in illegal conspiracies to “manipulate prices, reduce competition” and restrain trade for more than 100 generic drugs.
E+F patent attorney elevated to partner
Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
Diabetics to benefit under latest FDA biosimilar guidance
The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
Novartis to boost eye care portfolio with $3.4bn buy
Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.
Federal Circuit backs Sandoz in Amgen biosimilar suit
The US Court of Appeals for the Federal Circuit yesterday, May 8, rejected an appeal from Amgen in patent litigation relating to two Sandoz biosimilars.
Generic of Gilead’s HIV pre-exposure drug coming to market in 2020
A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.
Lundbeck to acquire Abide Therapeutics for $250 million
Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.
